Meeder Asset Management Inc. boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.0% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 92,850 shares of the biopharmaceutical company’s stock after purchasing an additional 2,671 shares during the quarter. Meeder Asset Management Inc.’s holdings in Gilead Sciences were worth $6,036,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Athena Capital Advisors LLC acquired a new position in Gilead Sciences during the fourth quarter valued at approximately $27,000. Capital Financial Planning LLC acquired a new position in Gilead Sciences during the fourth quarter valued at approximately $27,000. Advisors Preferred LLC acquired a new position in Gilead Sciences during the fourth quarter valued at approximately $31,000. Legacy Financial Advisors Inc. lifted its position in Gilead Sciences by 361.3% during the fourth quarter. Legacy Financial Advisors Inc. now owns 489 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 383 shares in the last quarter. Finally, Claybrook Capital LLC acquired a new position in Gilead Sciences during the fourth quarter valued at approximately $32,000. Hedge funds and other institutional investors own 80.20% of the company’s stock.

NASDAQ GILD opened at $62.95 on Friday. Gilead Sciences, Inc. has a 52 week low of $60.32 and a 52 week high of $79.61. The company has a debt-to-equity ratio of 1.19, a quick ratio of 3.30 and a current ratio of 3.38. The firm has a market cap of $80.29 billion, a PE ratio of 10.24, a PEG ratio of 4.12 and a beta of 1.16.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 EPS for the quarter, missing analysts’ consensus estimates of $1.70 by ($0.26). Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.52 billion. During the same period in the previous year, the firm posted $1.78 earnings per share. The company’s revenue for the quarter was down 2.6% on a year-over-year basis. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 6.23 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were given a dividend of $0.63 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.57. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.00%. The ex-dividend date was Thursday, March 14th. Gilead Sciences’s payout ratio is presently 40.98%.

A number of research analysts have weighed in on GILD shares. ValuEngine cut shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, February 13th. Mizuho set a $88.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Friday, March 22nd. BidaskClub cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, February 7th. Wells Fargo & Co reduced their price target on shares of Gilead Sciences from $95.00 to $89.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 5th. Finally, Oppenheimer raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $85.00 price target on the stock in a research report on Thursday, January 3rd. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. Gilead Sciences currently has a consensus rating of “Buy” and a consensus target price of $82.12.

In related news, Director John Francis Cogan sold 2,700 shares of Gilead Sciences stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $67.23, for a total value of $181,521.00. Following the completion of the sale, the director now owns 57,560 shares in the company, valued at $3,869,758.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Richard James Whitley sold 9,534 shares of Gilead Sciences stock in a transaction on Monday, April 1st. The stock was sold at an average price of $65.48, for a total transaction of $624,286.32. Following the completion of the sale, the director now owns 34,669 shares of the company’s stock, valued at approximately $2,270,126.12. The disclosure for this sale can be found here. Over the last three months, insiders have sold 42,102 shares of company stock worth $2,787,375. Corporate insiders own 0.20% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Gilead Sciences, Inc. (GILD) Position Raised by Meeder Asset Management Inc.” was first published by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.dailypolitical.com/2019/04/20/gilead-sciences-inc-gild-position-raised-by-meeder-asset-management-inc.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Further Reading: How to read a candlestick chart

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.